My contribution to a board
I would help a board understand whether its operating commitments are supported by the capacity and authority needed to fulfil them. My experience is particularly relevant where technical decisions, supply expectations and financial plans interact. I can examine a manufacturing proposal from the standpoint of the whole operating path, including work that is less visible than a new production line. I would ask how management knows where its constraint sits and which assumptions become invalid if demand or process behaviour changes.
I would also bring experience of a listed business with a continuing family investment, where professional management must explain decisions to directors and shareholders with different histories in the company. That experience does not make me an expert in every governance setting. It does help me distinguish respect for an organisation's legacy from acceptance of an operating assumption that no longer holds. My contribution would be practical challenge supported by evidence, with clear recognition of the executive team's authority and the specialist competence I would not replace.
Judgement in practice
01Keeping the remaining thirteen investigations visible
The investigation programme improved the ageing register substantially, but thirteen cases remained beyond ninety days. I brought that unresolved work to the board alongside the reduction from forty-seven and the four cases reopened during the period. This allowed directors to examine whether management had improved the work rather than simply the measure. An external board could expect me to ask similar questions about a favourable operating headline: what remains, how the classification changed and whether the people closest to the evidence agree with the account. I would seek the answer through the agreed oversight process, not instruct a technical team to reach a particular conclusion.
02Taking a higher revised capital estimate back to directors
The staged expansion review increased the proposed total from ¥7.2 billion to ¥7.6 billion after revealing additional support requirements. I did not present the initial pause as a cost-saving success. I explained that the revised proposal described more of the work necessary to obtain the intended capacity. The board could then make a better-informed choice, including whether the investment remained attractive. In another company, I would ask whether a phased approval is producing useful information and whether management has preserved the original assumptions for comparison. A staged process should improve the decision, not make the ultimate commitment harder to recognise.
03Retaining products that an efficiency ranking would remove
The portfolio review at Nerukawa left eleven of twenty-three studied variants unchanged and retained five with different planning arrangements. The operating burden was real, but it was not the only relevant fact. I required customer and specialist considerations to be examined before treating a product as expendable. A board contribution from this experience would be to question whether the proposed simplification has accounted for continuing obligations and transition cost. I would also challenge indefinite retention without a funded support plan. Both choices require an explanation; neither should be protected from scrutiny by a single commercial or operational measure.
My first year on a board
My induction would begin with the company's operating model, the authority attached to consequential technical decisions and the history of major commitments. I would read recent investment papers alongside the subsequent operating reviews, looking for assumptions that changed after approval. With the chair and executive team's agreement, I would visit relevant operations and listen to the people responsible for planning, investigation and customer delivery. These conversations should improve board understanding, not establish a private reporting route to one director.
During the first six months, I would identify two or three areas where my experience could sharpen the committee's questions. I would avoid importing a pharmaceutical procedure into a different industry simply because it was familiar. The organisation's own risks, obligations and specialist advice should determine the approach. By the end of the first year, I would want to understand how directors learn about an unresolved issue, how management tests a claimed improvement and whether board discussions lead to clear decisions. I would seek feedback from the chair on both the substance and proportion of my contribution, including occasions when a more concise question would have helped the executive team respond better.
Conflicts and their management
My current business creates potential conflicts through suppliers, distribution partners, technical service providers and investment relationships, as well as direct product competition. I would map these before accepting an appointment and maintain the disclosure as circumstances changed. Confidential manufacturing information, product plans and commercial terms from Aoritsune would not become resources for another company's decisions. A request for that access would be a reason to question the fit of the role.
Where a specific matter created a conflict, I would follow the company's agreed process for disclosure, access to papers and participation. A recurring conflict could make the appointment impractical even if individual meetings could be managed. I would review that question with the chair rather than assume recusal always solves it. Eighteen days is my current annual capacity, including preparation and visits. Any appointment requiring materially more, particularly during an exceptional event, would need an explicit review before acceptance.
My independence statement
I would disclose my executive appointment, shareholding interests and relevant business relationships before a nomination process advances. The company and its advisers should evaluate those facts against its applicable requirements. I would not describe myself as independent merely because a proposed seat is outside pharmaceuticals.
Governance learning and readiness
IICA Independent Directors’ Databank: Registered
I registered in the IICA Independent Directors' Databank in June 2026 while exploring future cross-border board work. I have not recorded a proficiency-assessment pass or claimed an exemption here. Registration is a preparation step, not an appointment or a conclusion about eligibility for a particular company.
- Director workshops on Japanese listed-company oversight and conflict disclosure
- Board simulations separating technical assurance from executive accountability
- Continuing study of cross-border director responsibilities and nomination processes